Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

364 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical recommendations for treatment of localized angiosarcoma: A consensus paper by the Italian Sarcoma Group.
Palassini E, Baldi GG, Sulfaro S, Barisella M, Bianchi G, Campanacci D, Fiore M, Gambarotti M, Gennaro M, Morosi C, Navarria F, Palmerini E, Sangalli C, Sbaraglia M, Trama A, Asaftei S, Badalamenti G, Bertulli R, Bertuzzi AF, Biagini R, Bonadonna A, Brunello A, Callegaro D, Cananzi F, Cianchetti M, Collini P, Comandini D, Curcio A, D'Ambrosio L, De Pas T, Dei Tos AP, Ferraresi V, Ferrari A, Franchi A, Frezza AM, Fumagalli E, Ghilli M, Greto D, Grignani G, Guida M, Ibrahim T, Krengli M, Luksch R, Marrari A, Mastore M, Merlini A, Milano GM, Navarria P, Pantaleo MA, Parafioriti A, Pellegrini I, Pennacchioli E, Rastrelli M, Setola E, Tafuto S, Turano S, Valeri S, Vincenzi B, Vitolo V, Ivanescu A, Paloschi F, Casali PG, Gronchi A, Stacchiotti S. Palassini E, et al. Among authors: d ambrosio l. Cancer Treat Rev. 2024 May;126:102722. doi: 10.1016/j.ctrv.2024.102722. Epub 2024 Mar 30. Cancer Treat Rev. 2024. PMID: 38604052 Free article. Review.
Pharmacokinetics, safety, and activity of trabectedin as first-line treatment in elderly patients who are affected by advanced sarcoma and are unfit to receive standard chemotherapy: A phase 2 study (TR1US study) from the Italian Sarcoma Group.
Grosso F, D'Ambrosio L, Zucchetti M, Ibrahim T, Tamberi S, Matteo C, Rulli E, Comandini D, Palmerini E, Baldi GG, DeCensi A, Bergaglio M, Marra D, Marchesi E, Siri G, D'Incalci M, Grignani G. Grosso F, et al. Cancer. 2020 Nov 1;126(21):4726-4734. doi: 10.1002/cncr.33120. Epub 2020 Aug 4. Cancer. 2020. PMID: 32749681 Free article. Clinical Trial.
Guideline-Based Follow-Up Outcomes in Patients With Gastrointestinal Stromal Tumor With Low Risk of Recurrence: A Report From the Italian Sarcoma Group.
D'Ambrosio L, Fumagalli E, De Pas TM, Nannini M, Bertuzzi A, Carpano S, Boglione A, Buonadonna A, Comandini D, Gasperoni S, Vincenzi B, Brunello A, Badalamenti G, Maccaroni E, Baldi GG, Merlini A, Mogavero A, Ligorio F, Pennacchioli E, Conforti F, Manessi G, Aliberti S, Tolomeo F, Fiore M, Sbaraglia M, Dei Tos AP, Stacchiotti S, Pantaleo MA, Gronchi A, Grignani G; Italian Sarcoma Group. D'Ambrosio L, et al. JAMA Netw Open. 2023 Nov 1;6(11):e2341522. doi: 10.1001/jamanetworkopen.2023.41522. JAMA Netw Open. 2023. PMID: 37930700 Free PMC article.
Imatinib rechallenge in patients with advanced gastrointestinal stromal tumors following progression with imatinib, sunitinib and regorafenib.
Vincenzi B, Nannini M, Badalamenti G, Grignani G, Fumagalli E, Gasperoni S, D'Ambrosio L, Incorvaia L, Stellato M, Spalato Ceruso M, Napolitano A, Valeri S, Santini D, Tonini G, Casali PG, Dei Tos AP, Pantaleo MA. Vincenzi B, et al. Ther Adv Med Oncol. 2018 Aug 29;10:1758835918794623. doi: 10.1177/1758835918794623. eCollection 2018. Ther Adv Med Oncol. 2018. PMID: 30181783 Free PMC article.
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group.
Grignani G, D'Ambrosio L, Pignochino Y, Palmerini E, Zucchetti M, Boccone P, Aliberti S, Stacchiotti S, Bertulli R, Piana R, Miano S, Tolomeo F, Chiabotto G, Sangiolo D, Pisacane A, Dei Tos AP, Novara L, Bartolini A, Marchesi E, D'Incalci M, Bardelli A, Picci P, Ferrari S, Aglietta M. Grignani G, et al. Lancet Oncol. 2018 Oct;19(10):1360-1371. doi: 10.1016/S1470-2045(18)30438-8. Epub 2018 Sep 11. Lancet Oncol. 2018. PMID: 30217671 Free article. Clinical Trial.
Sorafenib and everolimus for patients with unresectable high-grade osteosarcoma progressing after standard treatment: a non-randomised phase 2 clinical trial.
Grignani G, Palmerini E, Ferraresi V, D'Ambrosio L, Bertulli R, Asaftei SD, Tamburini A, Pignochino Y, Sangiolo D, Marchesi E, Capozzi F, Biagini R, Gambarotti M, Fagioli F, Casali PG, Picci P, Ferrari S, Aglietta M; Italian Sarcoma Group. Grignani G, et al. Lancet Oncol. 2015 Jan;16(1):98-107. doi: 10.1016/S1470-2045(14)71136-2. Epub 2014 Dec 11. Lancet Oncol. 2015. PMID: 25498219 Free article. Clinical Trial.
Personalization of regorafenib treatment in metastatic gastrointestinal stromal tumours in real-life clinical practice.
Nannini M, Nigro MC, Vincenzi B, Fumagalli E, Grignani G, D'Ambrosio L, Badalamenti G, Incorvaia L, Bracci R, Gasperoni S, Saponara M, Gatto L, Indio V, Astolfi A, Di Scioscio V, Casali PG, Tonini G, Aglietta M, Russo A, Biasco G, Pantaleo MA. Nannini M, et al. Ther Adv Med Oncol. 2017 Dec;9(12):731-739. doi: 10.1177/1758834017742627. Epub 2017 Dec 19. Ther Adv Med Oncol. 2017. PMID: 29449894 Free PMC article.
364 results